Top

Archives of Osteoporosis

Published in:

01-12-2020 | Thalassemia | Original Article

Bone mineral density among Palestinian patients suffering from hemoglobinopathy disorders

Authors: Akram Kharroubi, Bashar Karmi, Walaa Shamasneh, Elias Saba

Published in: Archives of Osteoporosis | Issue 1/2020

Abstract

Summary

This study aimed to investigate the correlation between bone mineral density (BMD) with hemoglobin and ferritin levels in Palestinian patients suffering from various types of hemoglobinopathies. The study revealed the thresholds of hemoglobin and ferritin to protect against low BMD in these patients.

Purpose

Iron overload is the main cause of low BMD in subjects with hemoglobinopathies. We used iron overload–related parameters like hemoglobin and ferritin to estimate the cutoff values required to maintain bone health and identify subjects with low BMD.

Methods

Palestinian patients (135) suffering from various types of hemoglobinopathies were recruited from various medical centers including 87 β thalassemia major (TM), 13 thalassemia intermedia (TI), 16 sickle cell anemia (SCA), 17 sickle cell thalassemia (SCT), and 1 thalassemia trait (TT). Most subjects (84%) were below the age of 30 years. BMD was measured and the z score was used to identify subjects with low BMD (z < − 2.0). Receiver operator characteristic (ROC) curve analysis was used to estimate the thresholds of hemoglobin and ferritin levels needed to protect against low BMD in these patients.

Results

No difference in means of age, weight, BMI, hemoglobin, and ferritin levels among the recruited male and female subjects were observed. The results showed that 77% of TM subjects had low BMD levels and femoral neck and total hip BMD were significantly lower among female compared to male subjects. Thalassemia patients (TM, TI, and SCT combined) had significantly low BMD and lower hemoglobin mean values compared to normal BMD subjects (8.54 vs. 9.25 g/dL, p = 0.01). Pearson’s correlation analysis showed positive correlation between hemoglobin levels and BMD at the three sites, being higher with lumbar spine (r = 0.444) compared to femoral neck (r = 0.291) and total hip (r = 0.224). Ferritin levels in TM patients (4800 ng/ml) and TI subjects (1500 ng/ml) were abnormally high. ROC curve analysis showed that hemoglobin threshold ≤ 9.3 g/dL represents a risk for developing low BMD with an area under the ROC curve (AUC) 0.699 and sensitivity and specificity were 87.9% and 47.7%, respectively. Similar analysis revealed that Ferritin threshold to protect against low BMD should be maintained below 2300 ng/ml with AUC 0.619 and sensitivity and specificity were 55.0% and 71.4%, respectively.

Conclusions

The results of this study strongly recommend to maintain hemoglobin levels above 9.3 g/dL and ferritin below 2300 ng/ml to protects against low BMD in TM subjects and patients suffering from the other related hemoglobinopathies.

Ahmad E, Shaheen M (2019) Prevalence of hypogonadism in thalassemia major patients in Gaza strip. Al-Azhar University of Gaza, pp 55-64

Al Sabbah H, Khan S, Hamadna A, Abu Ghazaleh L, Dudin A, Karmi BA (2017) Factors associated with continuing emergence of beta-thalassemia major despite prenatal testing: a cross-sectional survey. Int J Women's Health 9:673–679CrossRef

Aslan I, Canatan D, Balta N, Kacar G, Dorak C, Ozsancak A, Oguz N, Cosan R (2012) Bone mineral density in thalassemia major patients from antalya, Turkey. Int J Endocrinol 2012:573298CrossRef

Ayyash H, Sirdah M (2018) Hematological and biochemical evaluation of beta-thalassemia major (betaTM) patients in Gaza Strip: a cross-sectional study. Int J Health Sci (Qassim) 12:18–24

Baldini M, Forti S, Orsatti A, Marcon A, Ulivieri FM, Airaghi L, Zanaboni L, Cappellini MD (2014) Thalassemic osteopathy: a new marker of bone deposition. Blood Cells Mol Dis 52:91–94CrossRef

Balogh E, Paragh G, Jeney V (2018) Influence of iron on bone homeostasis. Pharmaceuticals (Basel) 11

Borgna-Pignatti C, Gamberini MR (2011) Complications of thalassemia major and their treatment. Expert Rev Hematol 4:353–366CrossRef

Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12:61–76CrossRef

Chon SJ, Choi YR, Roh YH, Yun BH, Cho S, Choi YS, Lee BS, Seo SK (2014) Association between levels of serum ferritin and bone mineral density in Korean premenopausal and postmenopausal women: KNHANES 2008-2010. PLoS One 9:e114972CrossRef

10.

Daraghmeh N (2016) Management and complications of thalassemic patients in Palestine: retrospective study. An-Najah National University, pp 39-42

11.

Darwish HM, El-Khatib FF, Ayesh S (2005) Spectrum of beta-globin gene mutations among thalassemia patients in the West Bank region of Palestine. Hemoglobin 29:119–132PubMed

12.

De Sanctis V, Soliman AT, Elsedfy H, Yassin M, Canatan D, Kilinc Y, Sobti P, Skordis N, Karimi M, Raiola G, Galati MC, Bedair E, Fiscina B, El Kholy M, I CET (2013) Osteoporosis in thalassemia major: an update and the I-CET 2013 recommendations for surveillance and treatment. Pediatr Endocrinol Rev 11:167–180PubMed

13.

De Sanctis V, Soliman AT, Elsefdy H, Soliman N, Bedair E, Fiscina B, Kattamis C (2018) Bone disease in beta thalassemia patients: past, present and future perspectives. Metabolism 80:66–79CrossRef

14.

Dede AD, Trovas G, Chronopoulos E, Triantafyllopoulos IK, Dontas I, Papaioannou N, Tournis S (2016) Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease. Osteoporos Int 27:3409–3425CrossRef

15.

Gaudio A, Morabito N, Catalano A, Rapisarda R, Xourafa A, Lasco A (2019) Pathogenesis of thalassemia major-associated osteoporosis: a review with insights from clinical experience. J Clin Res Pediatr Endocrinol 11:110–117CrossRef

16.

Giusti A, Pinto V, Forni GL, Pilotto A (2016) Management of beta-thalassemia-associated osteoporosis. Ann N Y Acad Sci 1368:73–81CrossRef

17.

Harteveld CL, Higgs DR (2010) α-thalassaemia. Orphanet J Rare Dis 5:13–21CrossRef

18.

Hashemieh M, Azarkeivan A, Radfar M, Saneifard H, Hosseini-Zijoud SM, Noghabaei G, Yaseri M (2014) Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic, Iran. IJBC 6:143–148

19.

Iancu EM, Albu AI, Nicolaescu I (2017) Risk factors associated with osteoporosis in beta-thalassaemia major patients. Endocr Abstr 49:EP307

20.

Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B (1998) High prevalence of low bone mass in thalassaemia major. Br J Haematol 103:911–915CrossRef

21.

Kharroubi A, Saba E, Smoom R, Bader K, Darwish H (2017) Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women. Arch Osteoporos 12:13CrossRef

22.

Kidson-Gerber GL, Francis S, Lindeman R (2008) Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic. Med J Aust 188:72–75CrossRef

23.

Langhi D Jr, Ubiali EM, Marques JF Jr, Verissimo MA, Loggetto SR, Silvinato A, Bernardo WM (2016) Guidelines on beta-thalassemia major - regular blood transfusion therapy: Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associacao Medica Brasileira - 2016. Rev Bras Hematol Hemoter 38:341–345CrossRef

24.

Meena MC, Hemal A, Satija M, Arora SK, Bano S (2015) Comparison of bone mineral density in thalassemia major patients with healthy controls. Advances in Hematology 2015:648349

25.

Nakhakesa C, Jaruluxanananb S, Saengsudac Y, Saengsudac S (2015) Risk factors for osteoporosis and the relationship between osteoporosis and hemoglobin level in adult patients with thalassemia in Rajavithi hospital. Asian Biomedicine 9:169–174

26.

Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE (2003) Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 21:402–408CrossRef

27.

Piriyakhuntorn P, Tantiworawit, Phimphilai M, Srichairatanakool S, Teeyasoontranon W, Rattanathammethee T, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, Charoenkwan P (2018) Prevalence and risk factors of low bone mineral density and fractures of young thalassemia patients. Blood 132:3636CrossRef

28.

Rafsanjani KA, Razzaghy-Azar M, Zahedi-Shoolami L, Vossough P, Modarres A, Taheri N (2009) Bone mineral density in β thalassemia major and intermedia, correlation with biochemical and hormonal profiles. IJBC 4:121–127

29.

Soliman A, De Sanctis V, Yassin M (2013) Vitamin D status in thalassemia major: an update. Mediterr J Hematol Infect Dis 5:e2013057CrossRef

30.

Toumba M, Skordis N (2010) Osteoporosis syndrome in thalassaemia major: an overview. J Osteoporos 2010:537673CrossRef

31.

Tsartsalis AN, Lambrou GI, Tsartsalis D, Savvidis C, Karantza M, Terpos E, Kanaka-Gantenbein C, Chrousos GP, Kattamis A (2018) The role of biphosphonates in the management of thalassemia-induced osteoporosis: a systematic review and meta-analysis. Hormones (Athens) 17:153–166CrossRef

32.

Tsartsalis AN, Lambrou GI, Tsartsalis DN, Papassotiriou I, Vlachou E, Terpos E, Chrousos GP, Kanaka-Gantenbein C, Kattamis A (2019) Bone metabolism markers in thalassemia major-induced osteoporosis: results from a cross-sectional observational study. Curr Mol Med 19:335–341CrossRef

33.

Tzoulis P, Ang AL, Shah FT, Berovic M, Prescott E, Jones R, Barnard M (2014) Prevalence of low bone mass and vitamin D deficiency in beta-thalassemia major. Hemoglobin 38:173–178CrossRef

34.

Voskaridou E, Terpos E (2008) Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev 6(Suppl 1):86–93PubMed

35.

Wong P, Fuller PJ, Gillespie MT, Kartsogiannis V, Kerr PG, Doery JC, Paul E, Bowden DK, Strauss BJ, Milat F (2014) Thalassemia bone disease: a 19-year longitudinal analysis. J Bone Miner Res 29:2468–2473CrossRef

36.

Wong P, Fuller PJ, Gillespie MT, Milat F (2016) Bone disease in thalassemia: a molecular and clinical overview. Endocr Rev 37:320–346CrossRef

37.

Yang WP, Chang HH, Li HY, Lai YC, Huang TY, Tsai KS, Lin KH, Lin DT, Jou ST, Lu MY, Yang YL, Chou SW, Shih SR. Iron Overload Associated Endocrine Dysfunction Leading to Lower Bone Mineral Density in Thalassemia Major. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz309. https://doi.org/10.1210/clinem/dgz309.PMID:31907538.

38.

Yildiz M, Canatan D (2005) Soft tissue density variations in thalassemia major: a possible pitfall in lumbar bone mineral density measurements by dual-energy X-ray absorptiometry. Pediatr Hematol Oncol 22:723–726CrossRef

39.

Zadeh MMH, Hussain HY, Al Faisal W, Muhasin M (2017) Osteoporosis and associated factors among thalassemia patients referred to bone mineral density screening -Dubai Hospital, 2014-2017. Clin Case Rep Rev 3:1–4CrossRef

Title: Bone mineral density among Palestinian patients suffering from hemoglobinopathy disorders
Authors: Akram Kharroubi
Bashar Karmi
Walaa Shamasneh
Elias Saba
Publication date: 01-12-2020
Publisher: Springer London
Keywords: Thalassemia
Sickle Cell Anemia
Published in: Archives of Osteoporosis / Issue 1/2020
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-020-00853-x

At a glance: The STEP trials

Springer Medicine

Bone mineral density among Palestinian patients suffering from hemoglobinopathy disorders

Abstract

Summary

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Early changes in bone turnover predict longer-term changes in bone mineral density but not trabecular bone score in frail older women

Experiences of using an activating spinal orthosis in women with osteoporosis and back pain in primary care

Do patients that fracture with normal DXA-measured BMD have normal bone?

Bone mineral density in young adults: the influence of vitamin D status, biochemical indicators, physical activity and body composition

Bone health impairment in patients with cerebral palsy

Association between diabetic neuropathy and osteoporosis in patients: a systematic review and meta-analysis